Skyepharma continues to make excellent progress in multiple areas of the business. flutiform® is building momentum with strong sales growth reported in Japan and development progress in additional indications and geographies. We note with interest the disclosure of SKP-2076 as a triple therapy combination product for asthma which, along with SKP-2075, could add significant value to the group’s respiratory franchise. Development is also being made in the oral side of the business, with a second t ....
26 Nov 2015
flutiform® momentum continues; pipeline advances
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
flutiform® momentum continues; pipeline advances
SkyePharma (SKP:LON) | 0 0 0.0% | Mkt Cap: 470.3m
- Published:
26 Nov 2015 -
Author:
N+1 Singer Team -
Pages:
7
Skyepharma continues to make excellent progress in multiple areas of the business. flutiform® is building momentum with strong sales growth reported in Japan and development progress in additional indications and geographies. We note with interest the disclosure of SKP-2076 as a triple therapy combination product for asthma which, along with SKP-2075, could add significant value to the group’s respiratory franchise. Development is also being made in the oral side of the business, with a second t ....